Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
4.025
-0.045 (-1.11%)
Streaming Delayed Price
Updated: 10:13 AM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
22
23
Next >
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
↗
March 18, 2024
This company's growth story is about to get moving with gusto.
Via
The Motley Fool
Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know
↗
March 14, 2024
Via
Benzinga
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
↗
March 13, 2024
Via
Benzinga
Truist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To Know
↗
March 07, 2024
Via
Benzinga
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
↗
March 07, 2024
Its revenue is set to grow, and one of its trials is no longer paused.
Via
The Motley Fool
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
↗
March 06, 2024
With its first approval in hand, attention is now on the top line.
Via
The Motley Fool
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
↗
March 01, 2024
Via
Benzinga
Spotlight on Iovance Biotherapeutics: Analyzing the Surge in Options Activity
↗
February 29, 2024
Via
Benzinga
Iovance Biotherapeutics: Q4 Earnings Insights
↗
February 28, 2024
Via
Benzinga
Iovance Biotherapeutics's Earnings: A Preview
↗
February 27, 2024
Via
Benzinga
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
March 04, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
↗
March 02, 2024
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?
Via
The Motley Fool
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
↗
February 29, 2024
A robust rally ended abruptly with the publication of the company's latest fundamentals.
Via
The Motley Fool
Is Iovance a Buy After Its First Regulatory Win?
↗
February 25, 2024
Iovance Biotherapeutics has found a new way to treat cancer.
Via
The Motley Fool
Unpacking the Latest Options Trading Trends in Iovance Biotherapeutics
↗
February 23, 2024
Via
Benzinga
Iovance Biotherapeutics Unusual Options Activity For February 22
↗
February 22, 2024
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
February 29, 2024
Via
Benzinga
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
↗
February 29, 2024
More gains might be on the way for this high-flying biotech stock.
Via
The Motley Fool
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
3 Stocks Flashing Recent Insider Buying Signals
↗
February 27, 2024
One way to spot an opportunity is by paying attention to insider buying stocks. After all, it’s the insiders that know their company.
Via
InvestorPlace
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
↗
February 26, 2024
Find out which under-the-radar biotech stocks have major catalysts on the horizon, and unlock their explosive growth potential.
Via
InvestorPlace
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
↗
February 26, 2024
A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof.
Via
The Motley Fool
This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst
↗
February 23, 2024
It has good news in hand and plenty of room to grow.
Via
The Motley Fool
2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value
↗
February 23, 2024
These two businesses have viable paths to making investors richer -- possibly soon.
Via
The Motley Fool
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
February 22, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
↗
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
February 21, 2024
Shares of International Flavors & Fragrances Inc. (NYSE: IFF) fell during Wednesday’s session after the company reported mixed fourth-quarter financial results and reduced its expected quarterly...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
February 21, 2024
Via
Benzinga
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) Near Top of Volume Charts in Wednesday Trading
February 21, 2024
Via
Investor Brand Network
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
